Abbott announced it would introduce high-sensitive troponin-I blood test in India, which can predict chances of a heart attack or other cardiac event months to years in advance.
“This life-changing technology has the potential to transform how doctors identify those at risk of for developing heart disease because the diagnostic test uses a biomarker specific to the heart. European guidelines currently recommend that doctors look at indirect heart health factors, such as a person’s cholesterol levels, blood pressure as well as if they have diabetes or are a smoker, to determine risk for developing heart disease,” the company said in a statement.
Cardiovascular diseases kill an estimated 17.7 million people globally, according to the World Health Organisation. Of those, 7.4 million were due to coronary heart disease. The company said its troponin-I test provides better predictive information for determining a person’s chances of developing future heart disease when added to the current standard of care. Troponin-I proteins are released from the heart and can be found at elevated levels in the blood when the heart muscle has been damaged due to lack of blood flow, according to the statement.
“Abbott’s High Sensitive Troponin-I blood test has been used in emergency rooms across Europe over the past five years to help physicians detect heart attacks faster and more accurately, particularly among women who often have lower troponin levels.” The troponin-I test can detect very low levels of troponin and can be used to determine cardiac risk in people with no reported symptoms of heart disease. “Using this diagnostic test during the same blood draw of a routine health exam, doctors will be able to look at what’s actually happening to the heart and better determine their patients’ risk of developing heart diseases, such as a heart attack or other cardiac event, in the future. “With this added information, doctors can help ensure the correct treatment is given to people at high risk and prevent unnecessary testing, medication, and costs for lower-risk patients.” “As we launch our test this week during World Heart Day, Abbott will work with physicians and laboratories in India to determine how this could fit within their existing practices for prevention or annual health check-ups,” said Narendra Varde, GM and country head at Abbott’s Diagnostics Business.